Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2015, Article ID 383509, 5 pages
http://dx.doi.org/10.1155/2015/383509
Research Article

Correlation and Significance of Urinary Soluble Fas and Vascular Endothelial Growth Factor in Bladder Urothelial Cancer

1Department of Andrology, First Hospital of Shijiazhuang, Shijiazhuang 050011, China
2Department of Urology, The First Hospital of Shijiazhuang, Shijiazhuang 050011, China
3Department of Urology, Affiliated Hospital to Chengde Medical College, Chengde 067000, China

Received 27 August 2015; Revised 30 November 2015; Accepted 1 December 2015

Academic Editor: Ja Hyeon Ku

Copyright © 2015 Huixiang Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Cheng, S. Zhang, G. T. MacLennan, S. R. Williamson, A. Lopez-Beltran, and R. Montironi, “Bladder cancer: translating molecular genetic insights into clinical practice,” Human Pathology, vol. 42, no. 4, pp. 455–481, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. H. F. O'Kane, C. J. Watson, S. R. Johnston et al., “Targeting death receptors in bladder, prostate and renal cancer,” The Journal of Urology, vol. 175, no. 2, pp. 432–438, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. E. Ulukaya, C. Acilan, M. Yilmaz et al., “sFas levels increase in response to cisplatin-based chemotherapy in lung cancer patients,” Cell Biochemistry and Function, vol. 28, no. 7, pp. 565–570, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Yang, H. Li, Z. Wang, J. Gao, and Y. Guo, “Is urinary soluble Fas an independent predictor of non-muscle-invasive bladder cancer? A prospective chart study,” Urologia Internationalis, vol. 91, no. 4, pp. 456–461, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. H. Yang, J. Gao, Z. Wang, and X. Zhai, “Detection of soluble Fas in urine for the diagnosis of bladder cancer,” China Journal of Modern Medicine, vol. 23, no. 7, pp. 38–41, 2013. View at Google Scholar
  6. R. S. Svatek, M. P. Herman, Y. Lotan et al., “Soluble Fas—a promising novel urinary marker for the detection of recurrent superficial bladder cancer,” Cancer, vol. 106, no. 8, pp. 1701–1707, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. Y. Ji, S. Chen, K. Li, X. Xiao, T. Xu, and S. Zheng, “Upregulated autocrine vascular endothelial growth factor (VEGF)/VEGF receptor-2 loop prevents apoptosis in haemangioma-derived endothelial cells,” The British Journal of Dermatology, vol. 170, no. 1, pp. 78–86, 2014. View at Publisher · View at Google Scholar
  8. A. Verma, J. Degrado, A. B. Hittelman, M. A. Wheeler, H. Z. Kaimakliotis, and R. M. Weiss, “Effect of mitomycin C on concentrations of vascular endothelial growth factor and its receptors in bladder cancer cells and in bladders of rats intravesically instilled with mitomycin C,” BJU International, vol. 107, no. 7, pp. 1154–1161, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. J.-X. Chen, N. Deng, X. Chen et al., “A novel molecular grading model: combination of Ki67 and VEGF in predicting tumor recurrence and progression in non-invasive urothelial bladder cancer,” Asian Pacific Journal of Cancer Prevention, vol. 13, no. 5, pp. 2229–2234, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. P. K. Kopparapu, S. A. Boorjian, B. D. Robinson et al., “Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer,” Anticancer Research, vol. 33, no. 6, pp. 2381–2390, 2013. View at Google Scholar · View at Scopus
  11. C.-L. Guo, X.-H. Yang, W. Cheng et al., “Expression of Fas/FasL in CD8+ T and CD3+ Foxp3+ Treg cells—relationship with apoptosis of circulating CD8+ T cells in hepatocellular carcinoma patients,” Asian Pacific Journal of Cancer Prevention, vol. 15, no. 6, pp. 2613–2618, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. X. L. Dai, S. L. Zhou, J. Qiu, Y. F. Liu, and H. Hua, “Correlated expression of Fas, NF-κB, and VEGF-C in infiltrating ductal carcinoma of the breast,” European Journal of Gynaecological Oncology, vol. 33, no. 6, pp. 633–639, 2012. View at Google Scholar · View at Scopus
  13. J. Codony-Servat, X. Garcia-Albeniz, C. Pericay et al., “Soluble FAS in the prediction of benefit from cetuximab and irinotecan for patients with advanced colorectal cancer,” Medical Oncology, vol. 30, no. 1, article 428, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Boroumand-Noughabi, H. R. Sima, K. Ghaffarzadehgan et al., “Soluble Fas might serve as a diagnostic tool for gastric adenocarcinoma,” BMC Cancer, vol. 10, article 275, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Mizutani, O. Yoshida, and B. Bonavida, “Prognostic significance of soluble Fas in the serum of patients with bladder cancer,” The Journal of Urology, vol. 160, no. 2, pp. 571–576, 1998. View at Publisher · View at Google Scholar · View at Scopus
  16. F. G. E. Perabo, R. H. Mattes, A. Wirger et al., “Soluble Fas and Fas-ligand in bladder cancer in vitro and in vivo,” Urologic Oncology, vol. 6, no. 4, pp. 163–169, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. A. K. Srivastava, P. K. Singh, D. Singh, D. Dalela, S. K. Rath, and M. L. B. Bhatt, “Clinical utility of urinary soluble Fas in screening for bladder cancer,” Asia-Pacific Journal of Clinical Oncology, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. Á. Pinto, A. Redondo, P. Zamora, B. Castelo, and E. Espinosa, “Angiogenesis as a therapeutic target in urothelial carcinoma,” Anti-Cancer Drugs, vol. 21, no. 10, pp. 890–896, 2010. View at Publisher · View at Google Scholar · View at Scopus